Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05584241
NA

Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure

Sponsor: University of Michigan

View on ClinicalTrials.gov

Summary

The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron emission tomography-based amyloid and tau burden and associated risk of conversion to Dementia-Alzheimer's Type. Healthcare access will be explored as potential barrier to or facilitator of behavior change.

Official title: Behavioral Change Following Culturally Informed Biomarker Disclosure in Alzheimer's Disease

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2023-02-20

Completion Date

2026-05

Last Updated

2026-01-08

Healthy Volunteers

No

Interventions

BEHAVIORAL

Diagnostic Disclosure Protocol

Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.

BEHAVIORAL

Biomarker Disclosure Protocol

Participants receive information about their cognitive test results and research diagnosis just like in the diagnostic disclosure protocol. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.

Locations (1)

The University of Michigan

Ann Arbor, Michigan, United States